Complete Story
 

03/16/2020

Live Updates: Coronavirus Deaths Pass 6,500 Worldwide

First participant in coronavirus vaccine trial given dose

A novel coronavirus vaccine trial in the US has now given a dose to its first participant, the National Institute of Allergy and Infectious Diseases announced Monday.

The study aims to enroll a total of 45 healthy adults over a six-week time frame. Each participant will receive two injections about a month apart in varying doses. 

The study, which is a Phase I trial, is meant to establish that the vaccine is safe and induces a desired response from participants' immune systems. Proving that the vaccine is effective in preventing COVID-19 infection, however, will require follow-up studies involving many more participants, which will take many more months, experts say.

Please select this link to read the complete article from CNN.

Printer-Friendly Version